FDA Approves New Oral Treatment for Rare Bone Disorder FOP

The U.S. FDA has approved Atebrioz (zilurgisertib) tablets for patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP). Developed by Mirum Pharmaceuticals and Incyte, this once-daily oral ALK2 inhibitor is the third approved treatment for the ultra-rare genetic disorder, aiming to reduce new heterotopic ossification. This approval provides a new therapeutic option for patients with a debilitating condition.